
-
Ikena Oncology NASDAQ:IKNA Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.
Location: | Website: www.ikenaoncology.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-63.78M
Cash
124.4M
Avg Qtr Burn
-11.5M
Short % of Float
1.44%
Insider Ownership
4.55%
Institutional Own.
87.61%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma | Phase 1b Data readout | |
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Failed Discontinued | |
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer | Failed Discontinued |